

Daniel F B Wright

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11904430/publications.pdf>

Version: 2024-02-01

49
papers

835
citations

516215

16
h-index

525886

27
g-index

49
all docs

49
docs citations

49
times ranked

1051
citing authors

#	ARTICLE	IF	CITATIONS
1	Interpreting population pharmacokinetic-pharmacodynamic analyses – a clinical viewpoint. <i>British Journal of Clinical Pharmacology</i> , 2011, 71, 807-814.	1.1	86
2	Understanding the time course of pharmacological effect: a PKPD approach. <i>British Journal of Clinical Pharmacology</i> , 2011, 71, 815-823.	1.1	74
3	Model-Informed Precision Dosing: Background, Requirements, Validation, Implementation, and Forward Trajectory of Individualizing Drug Therapy. <i>Annual Review of Pharmacology and Toxicology</i> , 2021, 61, 225-245.	4.2	74
4	Predicting allopurinol response in patients with gout. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 277-289.	1.1	46
5	Impaired response or insufficient dosage? – Examining the potential causes of –inadequate response– to allopurinol in the treatment of gout. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 44, 170-174.	1.6	43
6	A Bayesian Dose-Individualization Method for Warfarin. <i>Clinical Pharmacokinetics</i> , 2013, 52, 59-68.	1.6	41
7	Correlation Between Trough Plasma Dabigatran Concentrations and Estimates of Glomerular Filtration Rate Based on Creatinine and Cystatin C. <i>Drugs in R and D</i> , 2014, 14, 113-123.	1.1	38
8	Clinical decision-making: An essential skill for 21st century pharmacy practice. <i>Research in Social and Administrative Pharmacy</i> , 2019, 15, 600-606.	1.5	30
9	Development of a Bayesian Forecasting Method for Warfarin Dose Individualisation. <i>Pharmaceutical Research</i> , 2011, 28, 1100-1111.	1.7	27
10	The population pharmacokinetics of allopurinol and oxypurinol in patients with gout. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 1411-1421.	0.8	26
11	A proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin time. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 599-609.	1.1	25
12	The Association between Metformin Therapy and Lactic Acidosis. <i>Drug Safety</i> , 2019, 42, 1449-1469.	1.4	22
13	What do we learn from repeated population analyses?. <i>British Journal of Clinical Pharmacology</i> , 2015, 79, 40-47.	1.1	21
14	A philosophical framework for pharmacy in the 21st century guided by ethical principles. <i>Research in Social and Administrative Pharmacy</i> , 2018, 14, 309-316.	1.5	21
15	–Massive– metformin overdose. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 2923-2927.	1.1	20
16	A call for the appropriate application of clinical pharmacological principles in the search for safe and efficacious COVID-19 (SARS-CoV-2) treatments. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 707-711.	1.1	20
17	Individualising the dose of allopurinol in patients with gout. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2015-2026.	1.1	17
18	Spotlight Commentary: Model-informed precision dosing must demonstrate improved patient outcomes. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2238-2240.	1.1	17

#	ARTICLE	IF	CITATIONS
19	The intact nephron hypothesis as a model for renal drug handling. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 147-156.	0.8	17
20	Coagulation assays and plasma fibrinogen concentrations in real-world patients with atrial fibrillation treated with dabigatran. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 630-638.	1.1	16
21	Methods for Predicting Warfarin Dose Requirements. <i>Therapeutic Drug Monitoring</i> , 2015, 37, 531-538.	1.0	16
22	The "apparent clearance"™ of free phenytoin in elderly <i>vs.</i> younger adults. <i>British Journal of Clinical Pharmacology</i> , 2010, 70, 132-138.	1.1	14
23	The impact of diuretic use and <i>ABCG2</i> genotype on the predictive performance of a published allopurinol dosing tool. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 937-943.	1.1	11
24	Influence of Genotype on Warfarin Maintenance Dose Predictions Produced Using a Bayesian Dose Individualization Tool. <i>Therapeutic Drug Monitoring</i> , 2016, 38, 677-683.	1.0	10
25	A Joint Model for Vitamin K-Dependent Clotting Factors and Anticoagulation Proteins. <i>Clinical Pharmacokinetics</i> , 2017, 56, 1555-1566.	1.6	9
26	Dabigatran: rational dose individualisation and monitoring guidance is needed. <i>New Zealand Medical Journal</i> , 2012, 125, 148-54.	0.5	9
27	Frequency of CYP2C9 polymorphisms in polynesian people and potential relevance to management of gout with benzbromarone. <i>Joint Bone Spine</i> , 2014, 81, 160-163.	0.8	8
28	Metformin doses to ensure efficacy and safety in patients with reduced kidney function. <i>PLoS ONE</i> , 2021, 16, e0246247.	1.1	8
29	A general empirical model for renal drug handling in pharmacokinetic analyses. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1869-1872.	1.1	7
30	Relationships Between Allopurinol Dose, Oxypurinol Concentration and Urate "Lowering Response" In Search of a Minimum Effective Oxypurinol Concentration. <i>Clinical and Translational Science</i> , 2020, 13, 110-115.	1.5	6
31	Restricting maintenance allopurinol dose according to kidney function in patients with gout is inappropriate!. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1378-1379.	1.1	5
32	Understanding the association between metformin plasma concentrations and lactate. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 700-701.	1.1	5
33	Is the dose of dabigatran really more predictable than warfarin?. <i>British Journal of Clinical Pharmacology</i> , 2013, 76, 997-998.	1.1	4
34	Letter by Chin et al Regarding Article, "Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation: A RE-LY (Randomized) Trial." <i>Stroke</i> 2014; 45:137-138.	1.1	4
35	A factor VII-based method for the prediction of anticoagulant response to warfarin. <i>Scientific Reports</i> , 2018, 8, 12041.	1.6	4
36	Understanding the process of clinical judgement for pharmacists when making clinical decisions. <i>Research in Social and Administrative Pharmacy</i> , 2019, 15, 607-614.	1.5	4

#	ARTICLE	IF	CITATIONS
37	Kinetic-pharmacodynamic model for drugs with non-linear elimination: Parameterisation matters. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 196-198.	1.1	4
38	The pharmacokinetics of metformin in patients receiving intermittent haemodialysis. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1430-1443.	1.1	4
39	Therapeutic decision-making in primary care pharmacy practice. <i>Research in Social and Administrative Pharmacy</i> , 2021, 17, 326-331.	1.5	4
40	Learning More From the Dabigatran Concentrations in the RE-LY Study. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2746-2747.	1.2	3
41	Response to "Comment on "Massive" metformin overdose" by Chiew <i>et al.</i> . <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 2940-2941.	1.1	3
42	Evaluation of Assumptions Underpinning Pharmacometric Models. <i>AAPS Journal</i> , 2019, 21, 97.	2.2	3
43	Measuring the Development of Therapeutic-Decision-Making Skills by Practicing Pharmacists Undertaking a University-Based Postgraduate Clinical Qualification at Distance. <i>Pharmacy (Basel)</i> 10.78444/rgBTj/Overlo	1.078444	4
44	A Population Pharmacokinetic Model for 51Cr EDTA to Estimate Renal Function. <i>Clinical Pharmacokinetics</i> , 2017, 56, 671-678.	1.6	2
45	Evaluation of designs for renal drug studies based on the European Medicines Agency and Food and Drug Administration guidelines for drugs that are predominantly secreted. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 1401-1410.	1.1	2
46	Population Pharmacokinetics and Pharmacokinetic-Pharmacodynamics in <i>Clinical Pharmacology</i> . , 2018, , 1-26.		1
47	Does the intact nephron hypothesis provide a reasonable model for metformin dosing in chronic kidney disease?. <i>British Journal of Clinical Pharmacology</i> , 2021, , .	1.1	1
48	Science fiction has become reality: Best practice for future viral pandemics. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3385-3387.	1.1	0
49	Population Pharmacokinetics and Pharmacokinetic-Pharmacodynamics in <i>Clinical Pharmacology</i> . , 2020, , 903-927.		0